Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation

Area of Science:

• Oncology
• Molecular Diagnostics
• Biotechnology

Background:

• Circulating tumor DNA (ctDNA) is a key oncological marker in liquid biopsies.
• Advancements in ctDNA detection technology enable identification of extremely low mutant allele frequencies.
• FDA approvals highlight the growing clinical utility of ctDNA-based liquid biopsy kits.

Purpose of the Study:

• To review the utility of total cell-free DNA (cfDNA) measurement.
• To examine techniques for differentiating ctDNA from cfDNA.
• To assess the clinical utility of various ctDNA liquid biopsy kits.

Main Methods:

• Literature review of PubMed, clinicaltrials.gov, and FDA approvals.
• Analysis of company newsletters and relevant scientific articles.
• Evaluation of methodologies for ctDNA and cfDNA detection and differentiation.

Main Results:

• Total cfDNA shows potential as a prognostic marker but faces limitations for chemotherapy monitoring due to lack of standardization.
• Standardized ctDNA liquid biopsy kits are advancing, with ongoing clinical trials.
• Current ctDNA applications in screening and minimal residual disease detection are limited by sensitivity issues.

Conclusions:

• Further technological innovations, multi-omics approaches, and improved sampling are needed to enhance ctDNA detection sensitivity.
• Standardization is crucial for large-scale clinical validation of cfDNA and ctDNA assays.
• Liquid biopsies hold great promise but require additional research before widespread clinical adoption.